ArticleScience progress
A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the diagnostic and prognostic utility of serum DLL1 in acute-on-chronic liver failure patients with bacterial infections.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveBacterial infections (BIs) in decompensated cirrhosis are associated with high morbidity and mortality but remain diagnostically challenging due to limited conventional biomarker accuracy. We aim to evaluate the utility of serum Delta-like ligand 1 (DLL1) for BI detection in patients with decompensated cirrhosis.MethodsIn this dual-cohort prospective study, 320 hospitalized patients with decompensated cirrhosis were consecutively enrolled and stratified into derivation (n = 224) and independent validation (n = 96) cohorts. Serum DLL1 levels were quantified at admission with an enzyme-linked immunosorbent assay. Diagnostic performance was assessed through receiver operating characteristic (ROC) curve analysis and multivariable logistic regression.ResultsCompared with their noninfected counterparts, patients with decompensated cirrhosis and BI had elevated serum DLL1 levels (P < 0.001). DLL1 was an independent predictor of BIs (adjusted odds ratio (OR) = 5.495, 95% confidence interval (CI): 3.022-9.992) in multivariate analysis. DLL1 demonstrated robust diagnostic performance (area under the curve (AUC) = 0.863, 95% CI: 0.814-0.911), which was further improved when combined with C-reactive protein (CRP) in a dual-marker model (AUC = 0.918, P < 0.001) and validated in an independent cohort (AUC = 0.925). Decision curve analysis confirmed the clinical utility of this combination across threshold probabilities of 10% to 80%. Notably, DLL1 levels were weakly correlated with total bilirubin levels (Spearman's ρ=0.24, P < 0.001), suggesting limited confounding effects from hepatic inflammation.ConclusionSerum DLL1 was a clinically viable diagnostic biomarker for BIs in patients with decompensated cirrhosis and demonstrated weak confounding effects from hepatic dysfunction. The CRP-DLL1 combined model achieved superior diagnostic accuracy with cross-cohort validation robustness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.